OBJECTIVE To analyze the correlation between the resistance rate of Escherichia coli and defined daily dose system (DDDs) of antibiotics in our hospital from 2019 to 2023.
METHODS The detection rate, specimen distribution, department distribution, and resistance rate of Escherichia coli in the Second Affiliated Hospital of Hunan University of Chinese Medicine from 2019 to 2023 were analyzed. Pearson correlation coefficients analyzed the correlation between the resistance rate of Escherichia coli and DDDs.
RESULTS The isolation rate of Escherichia coli among gram-negative bacteria showed an increasing trend from 2019 to 2023 (P < 0.05). Escherichia coli was mainly distributed in specimens such as urine, pus, and sputum, and the departmental distribution was dominated by proctology and urology. The resistance rates of Escherichia coli to piperacillin/tazobactam, amikacin, meropenem, cefoxitin, and cefoperazone/sulbactam were all less than 30%, the resistance rate to ampicillin was higher than 80%. The DDDs of piperacillin/tazobactam, ciprofloxacin, moxifloxacin, cefazolin and ceftriaxone showed an increasing trend (P < 0.05), while cefmetazole showed a decreasing trend (P < 0.05). The DDDs of some antibiotics affected the resistance rate of other drugs in a highly correlated manner, the resistance rate of Escherichia coli to piperacillin/tazobactam was positively correlated with the DDDs of moxifloxacin (r=0.994, P=0.001), its resistance rate to cefazolin was negatively correlated with the DDDs of gentamicin (r=-0.900, P=0.037), the resistance rate to cefotaxime was positively correlated with the DDDs of ciprofloxacin (r=0.935, P=0.020), the resistance rate to azuron was negatively correlated with the DDDs of cefuroxime (r=-0.894, P=0.041), and the resistance rate to compound neonicotinoid was negatively correlated with the DDDs of piperacillin/tazobactam, ciprofloxacin, and ceftriaxone (r=-0.956, P=0.011;r=-0.957, P=0.011;r=-0.941, P=0.017, respectively).
CONCLUSIONS The isolation rate of Escherichia coli among gram-negative bacteria is on the rise, and the resistance rate is closely related to DDDs. Hospitals should strengthen the management of clinical use of antibiotics to delay the emergence of drug-resistant bacteria.